Neuropathy, ischemia (peripheral vascular disease) and foot infection are some of the characteristic features of diabetic foot. According to the International Journal of Diabetes in Developing Countries, around 15% of all diabetic individuals are at high risk of developing diabetic foot ulcers. Barefoot walking, late presentation by patients, and belief in alternative system of medicines are contributing factors to the increasing prevalence of diabetic foot ulcers. Considerable growth in therapeutic pipeline of diabetic foot ulcers is expected which could be primarily attributed to the rising incidence of diabetes due to unhealthy lifestyle majorly among people in urban areas. Introduction of novel wound healing agents in the form of ointments and sprays, advancements of anti-bacterial agents and growing healthcare cost-effectiveness are some of the factors directing the growth of therapeutic pipeline of diabetic foot ulcers.
In April 2009, Department of Surgery at the University of Arizona College of Medicine and OmegaGenesis Inc. signed an agreement for the development of potential remedies for diabetic foot ulcers. The collaboration involved joint work in support of potential remedies, to find the effective ways of treatment and education to medical professionals and patients globally. In November 2015, Omnio AB and ProMetic Life Sciences Inc. entered into a strategic research and development agreement for development of therapies for the treatment of diabetic foot ulcers. The therapeutic candidate formation involved conversion of plasma protein plasminogen into a biological product that accelerated the healing of otherwise very hard‐to‐treat wounds including diabetic foot ulcers. In March 2017, The Southern Arizona Limb Salvage Alliance signed an agreement with University of Arizona College of Medicine in Tucson for the research papers regarding diabetic foot ulcer and the use of a real-time smart textile-based system to monitor pressure offloading, since increased plantar foot pressure is a leading cause of ulceration.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of diabetic foot ulcer therapeutics include, CoMentis Inc., PluroGen Therapeutics, Inc, Dipexium Pharmaceuticals, Inc., Derma Sciences, Inc., Genentech, Inc., Medelis Inc., Lynch Biologics LLC, Oneness Biotech Co., Ltd., Merck Sharp & Dohme Corp., Charsire Biotechnology Corp., Izun Pharma Ltd, Lakewood-Amedex Inc. Energenesis Biomedical Co., Ltd, GlaxoSmithKline plc, Daewoong Pharmaceutical Co. Ltd., Microbion Corporation, Olympus Biotech Corporation, Oneness Biotech Co., Ltd., Pfizer Inc., Biotec Pharmacon ASA, Bayer AG, MacroChem Corporation, Skingenix, Inc., Dipexium Pharmaceuticals, Inc. and TaiGen Biotechnology Co., Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)